I'm skeptical credo. I checked the FDA's website to look for the agenda, and all I was able to find was that there was indeed on Nov. 20 a panel for "General Hospital and Personal Use Devices," however I was unable to figure out what the agenda was for that meeting. Would you be so kind as to provide a link that proves the FDA has decided to review the Taxus stent on Nov. 20? I just want to be sure that you're not spreading misinformation because I can't find a single press release that suggests the FDA has changed its agenda, and it seems like that would be news worth including on Reuters.
BSX board members are already pointing to your post as "proof" that the FDA has changed their plans, so it would be good if we could clear all this up quickly before anyone does anything stupid based on what you're posting.
During the BSX webcast yesterday, one of their management people broke into the conference to announce that the FDA panel would allow Taxus 4 to be included on 11/20, even though it was not on the original agenda. This was followed by applause from the BSX webcast participants.
Believe me, as someone who is still long on JNJ, I was not pleased to hear this.
Its true. Now their management feels that BSX is invincible, and that they will grab market share in the US and around the world. Their message on their web cast today was that they had a good, if not better DE stent than does Cordis, and that their product had superior stent delivery capability.
It was painful to sit through the webcast knowing that for whatever reason, J&J may be losing a dominating position on a strategic product. Perhaps the patent litigation can still save the day.